We reported here in 2015 that Iluvian, a unique drug implant devised by Alimera Sciences, had entered trials for treatment of diabetic macular edema (DME). The drug is a corticosteroid that has demonstrated effectiveness in the treatment of DME without the need for monthly injections. Jay Prensky, MD (investigator for Alimera Sciences) reported to the [Read More]
Category: Latest News
Headworn Video Devices Are Helping The Visually Impaired To See Better
by Dan Roberts (Updated 1/11/2019) Portable electronic magnifiers have come a long way in the past decade, improving clarity of vision for thousands. A natural development for those who prefer to have their hands free has been the creation of several types of headworn video devices, the leaders in the field being eSight, NuEyes, and [Read More]
Incidence of AMD Dramatically Declining
A recent observational study at the University of Wisconsin-Madison has found that the risk of developing age-related macular degeneration (AMD) has been dramatically lessening over three generations. After looking at follow-up data on 4,819 participants and their offspring in the Beaver Dam studies (1987-2013), Karen J. Cruickshanks, Ph.D. et al found that the incidence of [Read More]
Two Trials Take First Step Toward Stem Cell Treatment for AMD
Results from two new clinical trials have added support for the use of human embryonic stem cells as treatment for the dry form of macular degeneration. Stem cells injected into the eye appear to have replaced the missing cells damaged by the disease, with no serious side effects. One study suggests it may have even improved patients’ [Read More]
Seeing AI Now Available Outside of U.S.
We announced here in July that Microsoft had released Seeing AI, a free app that harnesses the power of Artificial Intelligence (AI) to audibly read text, identify objects, and describe people. The app was originally available only in the United States, but it is now also in the British, Irish and Australian App stores. It is still available only for iOS devices [Read More]